

Abbott India Limited Godrej BKC, Plot C-68,"G"Block, 15-16th Floor, Bandra-Kurla Complex, Sion Trombay Road, Near MCA Club, Bandra (E), Mumbai - 400 051. India

Registered Office: 3, Corporate Park, Mumbai - 400 071.India

Fax: (91-22) 5016 9400 E-mail: webmasterindia@abbott.com Website: www.abbott.co.in

CIN: L24239MH1944PLC007330

Tel: (91-22) 5046 1000/2000

**BSE Limited** Corporate Relationship Department Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400 001

June 14, 2021

Scrip Code: 500488

Dear Sirs,

Sub: Intimation under Regulation 23 (9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed, disclosure of related party transactions on a consolidated basis, in the format specified in the Accounting Standards for the year ended March 31, 2021.

The above disclosure is also available on the website of the Company i.e. www.abbott.co.in

This is for your information and record.

Kindly acknowledge the receipt of the same.

Thank you.

Yours faithfully, **Abbott India Limited** 

Krupa Anandpara **Company Secretary** 

Membership No.: ACS 16536

Encl: a/a

### **ABBOTT INDIA LIMITED**

# DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2021

### A) Parties where control exists:

**Ultimate Holding Company:** Abbott Laboratories, USA **Holding Company:** Abbott Capital India Ltd., UK

## B) Other related parties with whom transactions have taken place during the year :

## I) Fellow subsidiaries :

British Colloids Ltd., U.K.

Abbott Healthcare Products Ltd., U.K

Abbott Healthcare Private Ltd., India

Abbott International LLC, USA

Abbott Products Operations AG., Switzerland

Abbott Laboratories (Singapore) Pte Ltd., Singapore

Abbott GmbH, Germany

Alere Medical Private Limited, India

Abbott Laboratories S.A., Switzerland

Abbott Laboratories S.A., Dubai

Abbott Laboratories Services LLC, Sri Lanka Branch

St Jude Medical India Private Limited, India

### II) Key Management personnel and Independent directors:

Mr. Anil Joseph, Managing Director (w.e.f. July 1, 2020)

Mr. Ambati Venu, Non-executive Director (ceased to be the Managing Director effective close of business hours on February 29, 2020)

Mr. Munir Shaikh, Chairman

Mr. Rajiv Sonalker, Whole-Time Director

Mr. Krishna Mohan Sahni, Independent Director (ceased to be the Director effective close of business hours on October 28, 2019)

Ms. Anisha Motwani, Independent Director (w.e.f. April 25, 2018)

Mr. Sudarshan Jain, Independent Director (w.e.f. April 1, 2019)

Ms. Shalini Kamath, Independent Director (w.e.f. October 29, 2019)

### C) Transactions during the year :

# I) Transactions with the Holding Company during the year

(Rupees in Crores)

	For the year ended	For the year ended
	March 31, 2021	March 31, 2020
Abbott Capital India Ltd., UK		
Remittance of dividend	267.98	69.67

### II) Transactions with Fellow Subsidiaries during the year

### i) Remittance of dividend :

	For the year ended March 31, 2021	For the year ended March 31, 2020
British Colloids Ltd., U.K. Remittance of dividend	36.75	9.56
Abbott Healthcare Products Ltd., U.K.		
Remittance of dividend	93.62	24.34

### ii) Sales to fellow subsidiaries :

	For the year ended March 31, 2021	For the year ended March 31, 2020
Abbott Healthcare Private Ltd., India		
Sales of stock-in-trade	60.9	<b>4</b> 56.86
Sales of raw materials	0.7	47.12
Abbott Products Operations AG., Switzerland		
Sales of stock-in-trade	-	0.86
Abbott Laboratories Services LLC, Srilanka Branch		
Sale of capital goods	0.0	2 -

### iii) Purchases from fellow subsidiaries :

	For the year ended	For the year ended
	March 31, 2021	March 31, 2020
Abbott Healthcare Private Ltd., India		
Purchase of raw materials	0.07	4.92
Purchase of stock-in-trade	69.53	145.06
Abbott Products Operations AG., Switzerland		
Purchase of raw materials	316.48	297.28
Purchase of stock-in-trade	84.12	80.04
Alere Medical Private Limited, India		
Purchase of capital goods	0.01	-

## **ABBOTT INDIA LIMITED**

# DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2021

## iv) Other expenses to fellow subsidiaries :

(Rupees in Crores)

	For the year ended	For the year ended
	March 31, 2021	March 31, 2020
Abbott Healthcare Private Ltd., India		
Shared and support services	53.07	10.14
Promotional expenses	0.88	0.63
Conversion charges	15.64	16.63
Payment of lease liabilities*	33.16	32.89
Finance costs*	10.69	1.98
Electricity and communication expenses	0.92	0.72
Alere Medical Private Limited, India		
Promotional expenses	0.06	0.06

<sup>\*</sup>In the previous year, the Company adopted Ind AS 116 'Leases', with the date of initial application as April 1, 2019.

## v) Deposit to fellow subsidiary :

	For the year ended	For the year ended
	March 31, 2021	March 31, 2020
Abbott Healthcare Private Ltd., India		
Interest free additional security deposit paid	0.16	-

## vi) Reimbursements to and from fellow subsidiaries :

	Reimburs	Reimbursement to		ent from
	For the year ended March 31, 2021	For the year ended March 31, 2020	For the year ended March 31, 2021	For the year ended March 31, 2020
Abbott Healthcare Private Ltd., India				
Market research and other expenses	0.03	-	0.26	0.15
Abbott International LLC, USA				
Employee benefits expense, travel and other expenses	0.11	0.28	0.00	-
Abbott Laboratories (Singapore) Pte Ltd., Singapore				
Employee benefits expense, travel and other expenses	0.01	0.40	0.14	0.27
Abbott Products Operations AG., Switzerland				
Employee benefits expense, travel and other expenses	-	-	-	1.60
Abbott Laboratories S.A., Switzerland				
Employee benefits expense, travel and other expenses	-	-	0.00	0.10
Abbott GmbH, Germany				
Employee benefits expense, travel and other expenses	-	-	0.04	0.10
Abbott Laboratories Services LLC, Sri Lanka Branch				
Employee benefits expense, travel and other expenses	-	-	0.29	0.25

## vii) Income from fellow subsidiaries :

For the year ended	For the year ended
Warch 31, 2021	March 31, 2020
51.72	16.26
1.15	1.15
2.98	3.71
1.18	1.27
1.18	1.27
1.23	0.61
0.18	-
	March 31, 2021  51.72 1.15  2.98  1.18  1.23

## viii) Lease liabilities from fellow subsidiary :

	For the year ended	For the year ended
	March 31, 2021	March 31, 2020
Abbott Healthcare Private Ltd., India		
Recognition of lease liabilities*	-	134.55

<sup>\*</sup>In the previous year, the Company adopted Ind AS 116 'Leases', with the date of initial application as April 1, 2019.

### **ABBOTT INDIA LIMITED**

## DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2021

### ix) Key management personnel remuneration\*:

(Rupees in Crores)

	For the year ended March 31, 2021	For the year ended March 31, 2020
Mr. Anil Joseph, Managing Director (w.e.f. July 1, 2020) Mr. Ambati Venu, Non-executive Director (ceased to be the Managing Director effective close of business hours on	3.80	-
February 29, 2020)	-	7.15
Mr. Rajiv Sonalker, Whole-Time Director	3.86	3.30

<sup>\*</sup>During the year, as a part of the 'Long Term Incentive Program', Restricted Stock Units of Abbott Laboratories, USA carrying perquisite value of **Rs.2.96 Crores** (March 31, 2020: Rs.3.64 Crores) have been granted to the above employees. Also refer Note 38 (b).

Also, provision for post employment benefits as contribution to gratuity fund, leave encashment on retirement and other defined benefits which are made based on actuarial valuation on an overall Company basis are not included in remuneration to key management personnel.

### x) Non-Executive, Other Directors' sitting fees:

	For the year ended March 31, 2021	For the year ended March 31, 2020
Mr. Munir Shaikh, Chairman Mr. Krishna Mohan Sahni, Independent Director (ceased to be the Director effective close of business hours on October	0.15	0.11
28, 2019)	-	0.09
Ms. Anisha Motwani, Independent Director (w.e.f. April 25, 2018)	0.17	0.14
Mr. Sudarshan Jain, Independent Director (w.e.f. April 1, 2019)	0.15	0.12
Ms. Shalini Kamath, Independent Director (w.e.f. October 29, 2019)	0.15	0.06

#### D) Outstanding:

	As at March 31, 2021	As at March 31, 2020
Trade payable to fellow subsidiaries (Refer Note 20)		,
Abbott Products Operations AG., Switzerland	91.21	86.31
Abbott Healthcare Private Ltd., India	8.93	14.69
Abbott Laboratories (Singapore) Pte Ltd., Singapore	_ *	0.03
Abbott International LLC, USA	0.08	-
	100.22	101.03
Lease Liabilities to fellow subsidiary (Refer Note 5)		
Abbott Healthcare Private Ltd., India	110.71	133.18
	110.71	133.18
Other payable to fellow subsidiary (Refer Note 21)		
Abbott Healthcare Private Ltd., India	0.45	0.45
	0.45	0.45
Trade receivables from fellow subsidiaries (Refer Note 10)		
Abbott Healthcare Private Ltd., India	9.38	24.77
Abbott Products Operations AG., Switzerland	<u> </u>	0.26
	9.38	25.03
Other receivables from fellow subsidiaries (Refer Note 14)		
Abbott Products Operations AG., Switzerland	0.53	0.59
Abbott Healthcare Private Ltd., India	4.65	0.66
Abbott Laboratories Services LLC, Sri Lanka Branch	-	0.02
Abbott International LLC, USA	4.70	5.36
Abbott Laboratories S.A., Dubai	0.20	0.20
Abbott Laboratories (Singapore) Pte Ltd., Singapore	0.20	0.23
Abbott GmbH, Germany	-	0.1
St Jude Medical India Private Limited, India	0.23	0.67
Alere Medical Private Limited, India	0.19	-
	10.70	7.84
Loan and deposit to fellow subsidiaries		
Abbott Healthcare Private Ltd., India (Refer Note 5 and 6)	14.84	14.77

<sup>\*</sup> below Rs.50000

### Terms and conditions of transactions with related parties :

All transactions with related parties are made in the ordinary course of business and the same is at arm's length. Outstanding balances at the year end are unsecured and interest free and settlement occurs in cash. The Company has not recorded any impairment for receivables. This assessment is undertaken each financial year through examining the financial position of the related parties and the market in which related parties operate.